Lucid Diagnostics is a highly innovative medical device brand that focuses on diagnosing and treating esophageal conditions, including those caused by chronic heartburn which may lead to esophageal cancer. Their mission is to empower clinicians to save lives by accurately detecting Barrett's Esophagus (BE), a precursor condition to highly lethal esophageal cancer, in an office setting where it can be effectively managed or treated. Lucid Diagnostics is at the forefront of developing groundbreaking technology in this field.

They have introduced a non-invasive, office-based targeted cell collection device called EsoCheck, as well as a lab-based DNA biomarker test named EsoGuard. These innovative products aim to detect the early signs of Barrett's Esophagus and potential progression to esophageal cancer. In fact, Lucid's technology was recognized by the National Cancer Institute in their 2020 Annual Plan and Budget Proposal, proving its effectiveness.

The brand follows a two-phase strategy, with the first phase focusing on launching EsoGuard as a lab-developed test (LDT) and separately commercializing EsoCheck as an FDA 510(k)-cleared cell collection device. In the second phase, Lucid Diagnostics aims to obtain FDA approval for widespread screening using EsoGuard on samples collected by EsoCheck. Lucid Diagnostics is committed to revolutionizing esophageal cancer detection and prevention.

As a subsidiary of PAVmed Inc., they are dedicated to advancing medical technology for the benefit of patients worldwide. Explore their innovative solutions and learn more about their mission on their website